The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2019, taking place from today to 27 February in Paris, France. The analysis highlights the changing treatment landscape, with doctors and pharmaceutical companies evaluating an expanding range of molecularly-targeted anticancer drugs and immunotherapy.
* This article was originally published here
